Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Pönisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Röhrborn R, Hebenstreit K, Al-Ali HK, Jäkel N, Niederwieser D. Pönisch W, et al. Among authors: niederwieser d. Br J Haematol. 2013 Jul;162(2):202-9. doi: 10.1111/bjh.12361. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692564 Free article. Clinical Trial.
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Deininger M, Pönisch W, Krahl R, Leiblein S, Edel E, Lange T, Fiedler F, Freund M, Franke A, Pasold R, von Grünhagen U, Herold M, Dölken G, Hoffmann FA, Uhle R, Schultze W, Steglich J, Schwarzer A, Richter P, Winkelmann C, Kettner E, Dachselt K, Subert R, Schwalbe E, Doepper J, Helbig W, Niederwieser D; East German Study Group Haematology/Oncology (OSHO). Deininger M, et al. Among authors: niederwieser d. Bone Marrow Transplant. 2001 Jun;27(11):1125-32. doi: 10.1038/sj.bmt.1703057. Bone Marrow Transplant. 2001. PMID: 11551022 Clinical Trial.
Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study.
Mantovani L, Hasenclever D, Krahl R, Pönisch W, Herold M, Pasold R, Fiedler F, Dölken G, Kämpfe D, Schmoll HJ, Súbert R, Kubel M, Niederwieser D, Helbig W; East German Hematology and Oncology Group (OSHO). Mantovani L, et al. Among authors: niederwieser d. Leuk Lymphoma. 2002 Feb;43(2):265-74. doi: 10.1080/10428190290006035. Leuk Lymphoma. 2002. PMID: 11999557 Clinical Trial.
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.
Olavarria E, Reiffers J, Boque C, Sureda A, Meloni G, Michallet M, Clark RE, Blaise D, Carella AM, Cahn JY, Jouet JP, Rizzoli V, Van Biezen A, Gratwohl A, Goldman JM, Niederwieser D, Apperley JF. Olavarria E, et al. Among authors: niederwieser d. Br J Haematol. 2002 Sep;118(3):762-70. doi: 10.1046/j.1365-2141.2002.03600.x. Br J Haematol. 2002. PMID: 12181043 Free article.
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF. Niederwieser D, et al. Blood. 2003 Feb 15;101(4):1620-9. doi: 10.1182/blood-2002-05-1340. Epub 2002 Oct 3. Blood. 2003. PMID: 12393457 Free article.
623 results